Search Result

Results for "

gastric acid reducer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (8) Bombesin Receptor (1) Cholecystokinin Receptor (1) ERK (1) Histamine Receptor (2) Histone Demethylase (1) Isotope-Labeled Compounds (4) mAChR (1) MEK (1) Methionine Adenosyltransferase (MAT) (3) NF-κB (1) PD-1/PD-L1 (1) Proton Pump (9) Reactive Oxygen Species (2) Sodium Channel (1) Somatostatin Receptor (3) Thymidylate Synthase (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Endocrinology (11) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Amino Acid Derivatives Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00360

(Rac)-Sograzepide (Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220	Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-14289

Cimetidine 2 Publications Verification SKF-92334	Histamine Receptor Bacterial	Endocrinology Cancer
Cimetidine (SKF-92334) is an orally active and inverse histamine H2 receptor antagonist with a K_i of 0.6 μM. Cimetidine is a gastric acid reducer, and can be used for duodenal and gastric ulcers research. Cimetidine has anti-cancer and anti-inflammatory activity .

HY-17037

Pirenzepine dihydrochloride 1 Publications Verification LS 519; Pirenzepin dihydrochloride; Gastrozepin dihydrochloride	mAChR	Metabolic Disease Cancer
Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

HY-14289A

Cimetidine hydrochloride SKF-92334 hydrochloride	Histamine Receptor Bacterial	Endocrinology Cancer
Cimetidine (SKF-92334) hydrochloride is an orally active and inverse histamine H2 receptor antagonist with a K_i of 0.6 μM. Cimetidine hydrochloride is a gastric acid reducer, and can be used for duodenal and gastric ulcers research. Cimetidine hydrochloride has anti-cancer and anti-inflammatory activity .

HY-106550

Enprostil RS 84135	Others	Endocrinology
Enprostil (RS 84135) is a prostaglandin E2 derivative. Enprostil can inhibit amogastrin-stimulated gastric acid secretion, as well as reducing the secretion of pepsin. Enprostil can also serve as an antiulcer agent, used for research of duodenal or gastric ulcers .

HY-17037A

Pirenzepine LS 519 free base; Pirenzepin; Gastrozepin
Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells .

HY-P0107

RC-3095

RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

RC-3095
RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-P0107A

RC-3095 TFA	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

HY-17021B

Esomeprazole potassium salt (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021

Esomeprazole (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0954A

Oxyphencyclimine
Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm .

HY-155115

LSD1-IN-27	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .

HY-17021C

Esomeprazole hemistrontium (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-W357818

Glycinexylidide GX	Sodium Channel ERK MEK NF-κB	Cancer
Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local anesthetic that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .

HY-B1245

Salsalate 1 Publications Verification Salicylsalicylic acid; Disalicylic acid	Reactive Oxygen Species	Inflammation/Immunology
Salsalate, a non-acetylated salicylate, is an effective antirheumatic agent that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression. Salsalate can be used in the research of type 2 diabetes .

HY-17037S1

Pirenzepine-d8 dihydrochloride LS 519-d₈ dihydrochloride; Pirenzepin-d₈ dihydrochloride; Gastrozepin-d₈ dihydrochloride	Isotope-Labeled Compounds	Cancer
Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S

Esomeprazole-d3 sodium (S)-Omeprazole-d₃ sodium; (-)-Omeprazole-d₃ sodium	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17021S1

Esomeprazole-d3 (S)-Omeprazole-d₃; (-)-Omeprazole-d₃	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

HY-17023

Esomeprazole sodium (S)-Omeprazole sodium; (-)-Omeprazole sodium	Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B1245R

Salsalate (Standard) Salicylsalicylic acid (Standard); Disalicylic acid (Standard)	Reactive Oxygen Species	Inflammation/Immunology
Salsalate (Standard) is the analytical standard of Salsalate. This product is intended for research and analytical applications. Salsalate, a non-acetylated salicylate, is an effective antirheumatic agent that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression. Salsalate can be used in the research of type 2 diabetes .

HY-130522

6β-Prostaglandin I1 6β-PGI1	Others	Others
6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID₅₀ (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .

HY-13728

Plevitrexed ZD 9331; BGC9331	Thymidylate Synthase	Cancer
Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a K_i of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical . Plevitrexed is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-17023R

Esomeprazole sodium (Standard) (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)	Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-144181

MAT2A-IN-5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .

HY-144184

MAT2A-IN-6	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .

HY-144185

MAT2A-IN-7	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .

HY-142930

MAT2A-IN-3	Somatostatin Receptor	Cancer
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .

HY-142929

MAT2A-IN-2	Somatostatin Receptor	Cancer
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .

HY-142928

MAT2A-IN-1	Somatostatin Receptor	Cancer
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .

Glycinexylidide GX	Biochemical Assay Reagents
Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local anesthetic that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .

Xenin	Peptides	Neurological Disease Metabolic Disease
Xenin is a 25-amino acid peptide initially isolated from human gastric mucosa. Xenin is a gut hormone that can reduce food intake.

RC-3095 TFA	Bombesin Receptor	Inflammation/Immunology
RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist . RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice .

Alytesin	Peptides	Cardiovascular Disease Neurological Disease
Alytesin, a bombesin-like peptide, is found in extracts of the skin of Alytes obstetricans. Alytesin reduces gastric acid secretion and induces hypertension. Alytesin also induces short-term anorexigenic effects in neonatal chicks

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P0259

Xenin	Natural Products Source classification Endogenous metabolite	Others
Xenin is a 25-amino acid peptide initially isolated from human gastric mucosa. Xenin is a gut hormone that can reduce food intake.

Cat. No.	Product Name	Chemical Structure

HY-17037S1

Pirenzepine-d8 dihydrochloride
Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

Pirenzepine-d8 dihydrochloride

Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .